eticur
eticur is a German consumer cord blood and cord tissue stem cell banking brand operated by FamiCord AG, offering collection, cryopreservation, and long-term storage to expectant parents through a Germany-wide network of cooperating hospitals and a direct online configurator.
- Company typePrivate
- Founded2004
- HeadquartersMunich, Germany
- Headcount11–50
- GTM typeB2C
- OfferingServices
What eticur does
eticur is a German consumer cord blood and cord tissue stem cell banking service, organized as the national retail brand of FamiCord AG (part of the FamiCord Capital Group, described as Europe's leading stem cell bank). The company offers expectant parents the collection, processing, cryopreservation, and long-term storage of stem cells derived from umbilical cord blood (hematopoietic stem cells) and umbilical cord tissue (mesenchymal stem cells). Operations are anchored by a GMP-certified laboratory within the FamiCord Group, operating under German Medicines Act (AMG) manufacturing authorizations — §13 AMG for cord blood, and §20b and §20c AMG for cord tissue collection and storage. Collection is performed by a Germany-wide network of cooperating licensed childbirth facilities and affiliated obstetricians and midwives under FamiCord's manufacturing authorization.
The business is direct-to-consumer, targeting German expectant parents acquired through a multi-channel marketing mix: website content (eti.verse), Google Ads, Meta (Facebook/Instagram) advertising, YouTube, a 14-day email education course, a referral program (Eltern-werben-Eltern), and healthcare-professional referrals from gynecologists, midwives, and hospitals. Customers self-serve through an online configurator (konfigurator.eticur.de) that includes a clinic finder across the partner network, with sales support provided via a German-language hotline and email.
eticur generates revenue primarily through subscription storage contracts offered in three variants: Vorauszahlung (prepaid multi-year), Jahresabo (annual subscription from child's first birthday), and Monatsabo (monthly subscription from birth), each with a minimum two-year term and CPI-linked price adjustments. Additional monetization includes one-time start fees, optional quality testing, transport services, and replacement collection kits (eti.box). Revenue is structurally recurring once a sample is banked, with optional multi-child discounts under the prepaid plan and a €150 bilateral referral incentive. The legal entity is FamiCord AG, registered in Leipzig, Germany, with group leadership spanning CEO Jakub Baran, CFO Thomas Pfaadt, CMO Tomasz Baran, CCO Dr. Conelia Wittke-Kothe, and Supervisory Board Chairman Dr. Peter Greiner.
eticur firmographics
Firmographics- Name
- eticur
- Legal name
- FamiCord AG
- Website
- https://eticur.de
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- eticur is a German consumer cord blood and cord tissue stem cell banking brand operated by FamiCord AG, offering collection, cryopreservation, and long-term storage to expectant parents through a Germany-wide network of cooperating hospitals and a direct online configurator.
- Ownership category
- akta.pro rank
eticur industry classification
Industry- Product category
- Stem Cell Banking
- NAICS
- Blood and Organ Banks (621991)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
- akta.pro secondary industries
- Cell & Gene Therapy Chain-of-Identity/Chain-of-Custody Logistics (HLAGAMAE), Biologics, Vaccines & Ultra-Low Temperature (ULT) Storage (TLALABAG)
Keywords
Where eticur is headquartered
LocationHeadquarters
- HQ city
- Munich
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
eticur business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Cord Blood and Cord Tissue Banking — Subscription Model: eticur generates revenue primarily through recurring subscription fees paid by families for the collection, processing, cryopreservation, and long-term storage of cord blood and/or cord tissue stem cells. Three contract variants are offered: (1) Vorauszahlung (prepaid) — a one-time upfront payment covering an initial period plus annual storage fees thereafter; (2) Jahresabo (annual subscription) — a one-time start fee plus annual recurring fees starting from the child's first birthday; (3) Monatsabo (monthly subscription) — monthly fees starting from the date of birth. All contract variants have a minimum term of two years. The company also charges for optional services such as quality testing, transport of biological material to treatment centers, and replacement collection kits.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Vorauszahlung (Prepaid) — one-time upfront payment covering an initial period plus annual storage fees |
| Subscription | Annual | Jahresabo (Annual Subscription) — start fee plus annual recurring fees from child's first birthday |
| Subscription | Monthly | Monatsabo (Monthly Subscription) — monthly fees from date of birth |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels10 records
eticur product offering
Product offeringCore offering
eticur organizes the collection, processing, cryopreservation, and long-term storage of stem cells from umbilical cord blood and cord tissue for expectant parents in Germany. The biological material is collected at cooperating hospitals and birthing centers, then processed and stored in a GMP-certified laboratory operated within the FamiCord Group. Customers contract for storage services on prepaid, annual subscription, or monthly subscription plans with a minimum term of two years.
Product overview
eticur is a cord blood and cord tissue stem cell banking service operated by FamiCord AG. The company offers collection, processing, cryopreservation, and long-term storage of umbilical cord blood and cord tissue through a network of partner clinics across Germany. Customers can store cord blood (containing blood stem cells for treating blood diseases, immune deficiencies, and neurological disorders) and/or cord tissue (containing stem cells for cartilage, bone, muscle, and nerve cells). The service is available through three pricing plans: prepayment (one-time upfront payment), annual subscription, or monthly subscription. Additional offerings include the eti.box collection kit and the eti.verse educational content platform featuring pregnancy guides and a week-by-week pregnancy calendar.
Differentiator
Problem solved
Functional benefit
Products and services
- Nabelschnurblut (Cord Blood Banking) Umbilical cord blood collection, processing, cryopreservation, and long-term storage service for expectant parents. Contains blood stem cells (hematopoietic stem cells) that can regenerate all human blood cells and are used in treatments for blood diseases, immune deficiencies, and neurological disorders.
- Nabelschnurgewebe (Cord Tissue Banking) Umbilical cord tissue collection and storage service for expectant parents. Contains mesenchymal stem cells capable of forming cartilage, bone, muscle, and nerve cells, currently researched for treatment of widespread conditions such as osteoarthritis.
- eti.box (Collection Kit) Physical collection kit (Entnahmekit) provided to parents prior to delivery, containing the necessary materials and instructions for umbilical cord blood and tissue collection at partner clinics.
Quantifiable outcome
- Over 80 diseases treatable with cord blood stem cells
Companies that use eticur
Customer profileSegments1 record
Ideal customer profiles1 record
eticur technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
eticur partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- FamiCord AG (Parent Company)coreeticur is the consumer brand operated by FamiCord AG, a European stem cell banking group. FamiCord provides the GMP-certified laboratory infrastructure, regulatory authorizations (§ 13, § 20b, § 20c AMG), and corporate governance including board leadership (CEO Jakub Baran, CFO Thomas Pfaadt, CMO Tomasz Baran, CCO Dr. Conelia Wittke-Kothe). The group is described as Europe's leading stem cell bank.
- Cooperating Childbirth Facilities (Germany-wide network)coreeticur maintains contracts with a Germany-wide network of licensed childbirth facilities (Kooperierende Entbindungseinrichtungen) that perform the cord blood and cord tissue collection under FamiCord's manufacturing authorization. These facilities and their affiliated obstetricians and midwives are trained and contractually bound to eticur's collection protocols. The homepage references a clinic finder (Klinik-Netzwerk) listing all partner facilities.
- Trustpilotminoreticur sends post-invoice customer satisfaction survey invitations through Trustpilot (Trustpilot A/S, Copenhagen, Denmark). Reviews are published on Trustpilot's platform. The company shares customer email addresses, names, and internal booking numbers with Trustpilot for this purpose.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
eticur competitors and assessment
Company assessmentMarket position
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
eticur social profiles
Digital presenceeticur compliance and trust
Trust signalCompliance5 records
eticur financial estimates
Financial estimateRevenue estimate
Valuation estimate
eticur leadership team
Management profileNumber of profiles
Profiles6 records
eticur funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
eticur M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about eticur
What does eticur do?
eticur organizes the collection, processing, cryopreservation, and long-term storage of stem cells from umbilical cord blood and cord tissue for expectant parents in Germany. The biological material is collected at cooperating hospitals and birthing centers, then processed and stored in a GMP-certified laboratory operated within the FamiCord Group. Customers contract for storage services on prepaid, annual subscription, or monthly subscription plans with a minimum term of two years.
Is eticur a public or private company?
eticur is a private company. It is classified as corporate owned and is currently operating.
When was eticur founded?
eticur was founded in 2004. It employs 11 to 50 people.
Where is eticur based?
eticur is headquartered in Munich, Germany, in the Europe region.
How does eticur make money?
One revenue line is on record: cord Blood and Cord Tissue Banking — Subscription Model.
Does eticur have an API?
No public API is recorded for eticur.
What industry is eticur in?
eticur's product category is Stem Cell Banking. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAGAMAE, Cell & Gene Therapy Chain-of-Identity/Chain-of-Custody Logistics. Its NAICS code is 621991 and its SIC code is 2836.